Loading quotes...

Forecast

The analysts' average price target is €247.51 (+9.42%). The median is €245.53 (+8.55%).

Buy	18
Hold	15
Sell	0

News Go to news feed

Cardinal Health expects growth to normalize as specialty and at-home investments expand

Cardinal Health said fiscal 2027 growth should normalize after fiscal 2026’s unusually strong specialty growth, customer onboarding and acquisitions. Management highlighted double-digit earnings growth across all five operating segments in fiscal 2026 and said it will continue expanding specialty and at-home care through MSO platforms, bolt-on deals and diabetes-related acquisitions. The company is prioritizing automated small-parcel distribution for higher-value at-home products, plans three more automated distribution centers, and reported strong cash flow toward its $10 billion objective. » More on finance.yahoo.com
Cardinal Health expects growth in 2027 after strong fiscal 2026

Cardinal Health closed fiscal 2026 well above plan: normalized earnings per share exceeded the original forecast by more than $2.00, and all five operating segments delivered double-digit earnings gains, led by a 25% increase in specialty pharmaceutical distribution. The company has achieved roughly 90% of its target of $10 billion in cumulative free cash flow and cites progress in specialty pharma, managed services, at‑home solutions and GMPD. For 2027 management expects growth at or above the level of long‑term plan targets, but at a normalized pace; pressure from commodities and tariffs remains a risk. The acquisition pipeline is active, with the purchase of AdaptHealth’s diabetes business named the most significant upcoming transaction. » More on de.investing.com
Cardinal Health expects 13–15% EPS growth in 2027 and plans $1 billion in share buybacks

At the Morgan Stanley Healthcare Conference, Cardinal Health said it expects earnings per share to grow 13–15% in fiscal 2027 and plans $1 billion in share repurchases. Management emphasized broad execution of its strategy: pharmaceutical wholesale remains the core business, while specialty, BioPharma Solutions, home care, nuclear medicine and logistics are the growth drivers. Specialty growth is likely to slow compared with last year’s boom; tariffs and regulatory changes remain watchpoints that the company plans to address through price adjustments and contract structures. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Cardinal Health has already paid €1.78 in dividends. The last payout was in October.

Financials

In the last quarter, Cardinal Health had revenue of €55.95bn and net profit of €345.23m

(EUR)	June 2026	YoY
Revenue	55.95bn	9.63%
Gross profit	2.41bn	28.79%
Net profit	345.23m	70.25%
EBITDA	920.02m	62.58%

Fundamentals

Metric	Value
Market capitalization	€52.41bn
Number of shares	231.56m
52-week high/low	€231.16 - €160.53
Dividend yield	0.79%
Dividends TTM	€1.78
Beta	0.50
P/E ratio	35.00
PEG ratio	2.83
P/B ratio	-20.83
P/S ratio	0.23

Company profile

Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. It has a collaboration agreement with Journey Biosciences, Inc. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.